Science Explorer Back to mapMap
Discussion
Topic · Cardiology and Cardiovascular Medicine

Antiplatelet Therapy and Cardiovascular Diseases

Antiplatelet Therapy and Cardiovascular Diseases is a research topic within Cardiology and Cardiovascular Medicine. Science Explorer counts 32k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the use of antiplatelet therapy, including aspirin, clopidogrel, and ticagrelor, in the prevention of cardiovascular events, especially in the context of percutaneous coronary intervention. It also explores the impact of genetic polymorphisms, platelet reactivity, and bleeding risk on the efficacy and safety of antiplatelet drugs.

  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Platelet Reactivity
  • Cardiovascular Events
  • Percutaneous Coronary Intervention
  • Genetic Polymorphisms
  • Bleeding Risk
  • Thrombotic Events
  • CYP2C19 Genotype
Research works
32k
fractional, since 1950
In the world top 10%
3.2k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-5%
the tick is no change
Largest producer
United States
34% of the 10 largest, 2022-now
Antiplatelet Therapy and Cardiovascular Diseases

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Antiplatelet Therapy and Cardiovascular Diseases research?

By volume, the United States and China publish the most (1.2k and 696 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.2k works
  2. 2 China 696 works
  3. 3 Italy 273 works
  4. 4 United Kingdom 224 works
  5. 5 Japan 218 works
  6. 6 Germany 217 works
  7. 7 South Korea 215 works
  8. 8 India 193 works
  9. 9 France 130 works
  10. 10 Spain 129 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 34.4%China: 19.9%Italy: 7.8%United Kingdom: 6.4%6 others listed: 31.5%34%largest
United States1,206 · 34.4%China696 · 19.9%Italy273 · 7.8%United Kingdom224 · 6.4%6 others listed1,102 · 31.5%

Shares of the rows listed above, not of the whole node.

Which institutions lead Antiplatelet Therapy and Cardiovascular Diseases research?

By volume in 2022-now, Harvard University publishes the most Antiplatelet Therapy and Cardiovascular Diseases research, followed by Capital Medical University and Chinese Academy of Medical Sciences & Peking Union Medical College.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 62 works
  2. 2 Capital Medical UniversityChina 41 works
  3. 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 40 works
  4. 4 Mount Sinai Health SystemUnited States 30 works
  5. 5 Mayo ClinicUnited States 28 works
  6. 6 University of North Carolina at Chapel HillUnited States 28 works
  7. 7 Yonsei UniversitySouth Korea 25 works
  8. 8 Seoul National UniversitySouth Korea 24 works
  9. 9 InsermFrance 20 works
  10. 10 University of MichiganUnited States 19 works

Who are the leading researchers in Antiplatelet Therapy and Cardiovascular Diseases?

The most-cited researchers publishing on Antiplatelet Therapy and Cardiovascular Diseases include David Moher, George Davey Smith and Walter Churchill Willett.

  1. 1 David Moher Canada 898k citations
  2. 2 George Davey Smith United Kingdom 435k citations
  3. 3 Walter Churchill Willett United States 411k citations
  4. 4 Julian P. T. Higgins United Kingdom 390k citations
  5. 5 John J.V. McMurray United Kingdom 349k citations
  6. 6 Hermann Brenner Germany 343k citations
  7. 7 Cyrus Cooper United Kingdom 342k citations
  8. 8 Emelia J. Benjamin United States 341k citations
  9. 9 Valery L. Feigin New Zealand 341k citations
  10. 10 Stephan Windecker Switzerland 338k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Antiplatelet Therapy and Cardiovascular Diseases?

The most cited paper in Antiplatelet Therapy and Cardiovascular Diseases is "Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis" (Qinghua Zhang, Chao Wang, Maoyong Zheng et al., 2014), with 11,556 citations. Next come "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)" (8,531) and "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes" (7,154).

Most cited papers
#PaperReleasedCitations
1 Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis Qinghua Zhang, Chao Wang, Maoyong Zheng et al. · Cerebrovascular Diseases ReviewOpen access 24 Dec 2014 11,556
2 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Authors/Task Force Members: et al. · European Heart Journal Open access 3 May 2012 8,531
3 Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes Lars C. Wallentin, Richard C. Becker, Andrzej Budaj et al. · New England Journal of Medicine Open access 30 Aug 2009 7,154
4 Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine Open access 4 Nov 2007 6,822
5 Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigato · New England Journal of Medicine Open access 16 Aug 2001 6,519
All 100 most cited papers, with filters and sorting

Where is Antiplatelet Therapy and Cardiovascular Diseases research done?

The largest centres of Antiplatelet Therapy and Cardiovascular Diseases research in 2022-now are Beijing (China), Seoul (South Korea), New York (United States) and Moscow (Russia).

Largest cities, 2022-now

  1. 1 BeijingChina 152 works
  2. 2 SeoulSouth Korea 115 works
  3. 3 New YorkUnited States 77 works
  4. 4 MoscowRussia 67 works
  5. 5 TokyoJapan 62 works
  6. 6 LondonUnited Kingdom 61 works
  7. 7 BostonUnited States 60 works
  8. 8 ParisFrance 55 works
  9. 9 RomeItaly 48 works
  10. 10 ShanghaiChina 42 works
See Antiplatelet Therapy and Cardiovascular Diseases on the map

Where is the best place to study Antiplatelet Therapy and Cardiovascular Diseases?

Among universities, judged by research, Harvard University, University of Liverpool and Maastricht University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 17.91%fractional works in this field (log) →share of work in the world top 10% →University of Liverp…Florida CollegeMaastricht UniversityHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 75.013.8%4.4×62 -13.2%
2University of LiverpoolUnited Kingdom 64.620.4%6.1×15 -12.6%
3Maastricht UniversityNetherlands 64.319.3%7.3×13 -15.3%
4Florida CollegeUnited States 61.020.1%18.7×11 -0.0%
5Karolinska InstitutetSweden 60.121.2%4.2×10 -11.6%
6University of FloridaUnited States 60.020.8%3.3×16 -7.1%
7Case Western Reserve UniversityUnited States 59.319.6%4.5×12 +59.8%
8Medical University of ViennaAustria 58.614.4%10.8×15 +6.6%
9Yonsei UniversitySouth Korea 57.613.0%6.3×25 +37.5%
10University of MichiganUnited States 57.616.5%2.8×19 +12.8%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Antiplatelet Therapy and Cardiovascular Diseases, country by country

Is Antiplatelet Therapy and Cardiovascular Diseases research growing?

Output in 2022-2025 was 5% lower than in 2018-2021, peaking in 2025.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Antiplatelet Therapy and Cardiovascular Diseases as a percentage of every work published that year, 0.021% in 2024.

still counting0.020%0.040%0.060%Antiplatelet Therapy and Cardiovascular Diseases0.021% in 202519801990200020102020

Fractional works of Antiplatelet Therapy and Cardiovascular Diseases over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Antiplatelet Therapy and Cardiovascular Diseases10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Antiplatelet Therapy and Cardiovascular Diseases. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.